Time-lapse mapping of cortical changes in schizophrenia with different treatments

Cerebral Cortex

Volumn 19, Issue 5, 2009, Pages 1107-1123

  Thompson, Paul M ^a   Bartzokis, George ^a   Hayashi, Kiralee M ^a   Klunder, Andrea D ^a   Lu, Po H ^a   Edwards, Nancy ^a   Hong, Michael S ^a   Yu, Michael ^a   Geaga, Jennifer A ^a   Toga, Arthur W ^a   Charles, Cecil ^b   Perkins, Diana O ^c   McEvoy, Joseph ^b   Hamer, Robert M ^c   Tohen, Mauricio ^d,e   Tollefson, Gary D ^d   Lieberman, Jeffrey A ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e MCLEAN HOSPITAL   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Cortex; Development; Imaging; Neurotoxicity; Schizophrenia

Indexed keywords

CLOZAPINE; HALOPERIDOL; OLANZAPINE; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN CORTEX; BRAIN MAPPING; BRAIN MATURATION; BRAIN SIZE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FRONTAL CORTEX; GLIA; GRAY MATTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE CONDUCTION; NEUROIMAGING; NEUROPROTECTION; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SYMPTOM; TIME PERCEPTION; TREATMENT DURATION; BRAIN; DRUG EFFECT; LONGITUDINAL STUDY; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; BRAIN MAPPING; DISEASE PROGRESSION; FEMALE; HALOPERIDOL; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 67649224058     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhn152     Document Type: Article

References (79)

1. Arango C, Kahn R. 2008. Progressive brain changes in schizophrenia. Schizophr Bull. 34(2):310-311.
2. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP, Fowler JS, Volkow ND, Smith G, Wolkin A. 1994. Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry. 151:681-686.
3. Bartzokis G, Nuechterlein KH, Lu PH, Gitlin M, Rogers S, Mintz J. 2003. Dysregulated brain development in adult men with schizophrenia: a magnetic resonance imaging study. Biol Psychiatry. 53:412-421.
4. Bearden CE, Thompson PM, Dalwani M, Hayashi KM, Lee AD, Nicoletti M, Trakhtenbroit M, Glahn DC, Brambilla P, Sassi RB, et al. 2007. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry. 62:7-16.
5. Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Cooper-Langston K, Kessler R. 1987. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol Psychiatry. 22:479-494.
6. Cahn W, van Haren NE, Hulshoff Pol HE, Schnack HG, Caspers E, Laponder DA, Kahn RS. 2006. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. Br J Psychiatry. 189:381-382.
7. Cannon TD, Hennah W, van Erp TGM, Thompson PM, Lonnqvist J, Huttunen M, Gasperoni T, Tuulio-Henriksson Pirkola T, Toga AW, et al. 2005. DISC1/TRAX haplotypes associate with schizophrenia, reduced prefrontal gray matter, and impaired short- and long-term memory. Arch Gen Psychiatry. 62:1205-1213.
8. Cannon TD, van Erp TGM, Bearden CE, Loewy R, Thompson PM, Toga AW, Huttunen MO, Keshavan M, Seidman LJ, Tsuang MT. 2003.
9. Early and Late Neurodevelopmental influences in the Prodrome to Schizophrenia: Contributions of Genes, Environment, and their Interactions. Schizophr Bull. 29(4):653-669.
10. Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M. 1995. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet. 345:456-457.
11. Chiang MC, Reiss AL, Lee AD, Bellugi U, Galaburda AM, Korenberg J, Mills DL, Toga AW, Thompson PM. 2007. 3D pattern of brain abnormalities in Williams syndrome visualized using tensor-based morphometry. Neuroimage. 36:1096-1109.
12. Chlan-Fourney J, Ashe P, Nylen K, Juorio AV, Li XM. 2002. Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration. Brain Res. 954:11-20.
13. Collins DL, Holmes CJ, Peters TM, Evans AC. 1995. Automatic 3-D model-based neuroanatomical segmentation. Hum Brain Mapp. 3:190-208.
14. Dazzan P, Morgan KD, Orr K, Hutchinson G, Chitnis X, Suckling J, Fearon P, McGuire PK, Mallett RM, Jones PB, et al. 2005. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology. 4:765-774.
15. DeLisi LE, Sakuma M, Tew W, Kushner M, Hoff AL, Grimson R. 1997. Schizophrenia as a chronic active brain process: a study of progressive brain structural change subsequent to the onset of schizophrenia. Psychiatry Res. 74:129-140.
16. Dorph-Petersen KA, Pierri JN, Perel JM, Sun Z, Sampson AR, Lewis DA. 2005. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue flxation: a comparison of haloperidol and olanzapine in Macaque monkeys. Neuropsychopharmacology. 30:1649-1661.
17. Duncan GE, Miyamoto S, Leipzig JN, Lieberman JA. 2000. Comparison of the effects of clozapine, risperidone, and olanzapine on ketamineinduced alterations in regional brain metabolism. J Pharmacol Exp Ther. 293(1):8-14.
18. Edgington ES. 1995. Randomization tests. New York: Marcel Dekker. Evans AC, Collins DL, Holmes CJ. 1996. Automatic 3D regional MRI segmentation and statistical probabilistic anatomical maps. New York: Academic Press.
19. Glantz LA, Gilmore JH, Lieberman JA, Jarskog LF. 2006. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr Res. 81:47-63.
20. Goff DC, Tsai G, Beal MF, Coyle JT. 1995. Tardive dyskinesia and substrates of energy metabolism in CSF. Am J Psychiatry. 152:1730-1736.
21. Gogtay N, Giedd JN, Lusk L, Hayashi KM, Greenstein D, Vaitiuzis C, Nugent TF, Herman DH, Classen L, Toga AW, Rapoport JL, et al. 2004. Dynamic mapping of human cortical development during childhood and adolescence. Proc Natl Acad Sci USA. 101:8174-8179.
22. Gogtay N, Lu A, Leow AD, Klunder AD, Lee AD, Chavez A, Greenstein D, Giedd JN, Toga AW, Rapoport JL, Thompson PM. Forthcoming. 3D Brain Growth Abnormalities in Childhood-Onset Schizophrenia Visualized using Tensor-Based Morphometry. Proc Natl Acad Sci USA.
23. Goldner EM, Hsu L, Waraich P, Somers JM. 2002. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry. 47:833-843.
24. Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC. 1998. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry. 55:145-152.
25. Harrison PJ, Lewis DA. 2003. Neuropathology of schizophrenia. In: Hirsch SR, Weinberger DR, editors. Schizophrenia. 2nd ed. Oxford: Blackwell Science. p. 310-325.
26. Harrow M, Grossman LS, Herbener ES, Davies EW. 2000. Ten-year outcome: Patients with schizoaffective disorders, schizophrenia, affective disorders and mood-incongruent psychotic symptoms. Brit J Psychiatry. 177:421-426.
27. Heinrichs DW, Hanlon TE, Carpenter WT. 1984. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 10:388-398.
28. Heitmiller DR, Nopoulos PC, Andreasen NC. 2004. Changes in caudate volume after exposure to atypical neuroleptics in patients with schizophrenia may be sex-dependent. Schizophr Res. 66:137-142.
29. Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. 2003. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry. 60:585-594.
30. Hof PR, Haroutunian V, Friedrich VL Jr, Byne W, Buitron C, Perl DP, Davis KL. 2003. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry. 53:1075-1085.
31. Holcomb HH, Cascella NG, Thaker GK, Medoff DR, Dannals RF, Tamminga CA. 1996. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am J Psychiatry. 153:41-49.
32. Job DE, Whalley HC, Johnstone EC, Lawrie SM. 2005. Grey matter changes over time in high risk subjects developing schizophrenia. Neuroimage. 25:1023-1030.
33. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW. 2002. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 63:763-771.
34. Kapur S, Seeman P. 2000. Antipsychotic agents differ in how fast they come off the dopamine D-2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 25:161-166.
35. Kay SR, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 13:261-276.
36. Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, et al. 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 64:633-647.
37. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RR, Yurgelun-Todd DA, Gur RC, Tohen M, et al. 2004. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 161:985-995.
38. Kempf L, Hussain N, Potash JN. 2005. Mood disorder with psychotic features, schizoaffective disorder, and schizophrenia with mood features: trouble at the borders. Int Rev Psychiatry. 17:9-19.
39. Keshavan MS, Anderson S, Pettegrew JW. 1994. Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res. 28:239-265.
40. Kondradi C, Heckers S. 2001. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry. 50(10):729-742.
41. Kubicki M, McCarley RW, Shenton ME. 2005. Evidence for white matter abnormalities in schizophrenia. Curr Opin Psychiatry. 18: 121-134.
42. Leow AD, Klunder AD, Jack CR, Toga AW, Dale AM, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Whitwell JL, et al. 2006. For the ADNI Preparatory Phase Study (2006). Longitudinal Stability of MRI for Mapping Brain Change using Tensor-Based Morphometry. NeuroImage. [Epub ahead of print].
43. Lieberman JA. 1999. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 46:729-739.
44. Lieberman JA. 2007. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry. 68:e04.
45. Lieberman JA, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J. 2001. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology and therapeutic approaches. Biol Psychiatry. 50:884-897.
46. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, et al. 2005. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry. 62:361-370.
47. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, et al. 2003.
48. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 160:1396-1404.
49. Lin JJ, Salamon N, Lee AD, Dutton RA, Geaga JA, Hayashi KM, London ED, Luders E, Toga AW, Engel J, Thompson PM. 2006. Reduced Neocortical Thickness & Complexity Mapped in Mesial Temporal Lobe Epilepsy with Hippocampal Sclerosis. Cereb Cortex. [Epub ahead of print].
50. Lyoo IK, Sung YH, Dager SR, Friedman SD, Lee JY, Kim SJ, Kim N, Dunner DL, Renshaw PF. 2006. Regional cerebral cortical thinning in bipolar disorder. Bipolar Disord. 8:65-74.
51. MacDonald D. 1998. A method for identifying geometrically simple surfaces from three dimensional images. PhD Thesis, McGill University, Canada.
52. McGlashan TH, Hoffman RE. 2000. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen Psychiatry. 57(7):637-648.
53. Marx CE, VanDoren MJ, Duncan GE, Lieberman JA, Morrow AL. 2003. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology. 28:1-13.
54. Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. 2001. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 58:148-157.
55. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, et al. 2006. Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry. 163:790-799.
56. Molina V. 2005. Structural effects of atypical antipsychotics: implications for the meaning of cortical volume deficit in schizophrenia. Eur J Psychiatry. 19:231-242.
57. Narr KL, Toga AW, Szeszko P, Thompson PM, Woods RP, Robinson D, Sevy S, Wang Y, Schrock K, Bilder RM. 2005. Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol Psychiatry. 58:32-40.
58. Narr KL, Woods RP, Thompson PM, Szeszko P, Robinson D, Dimtcheva T, Gurbani M, Toga AW, Bilder RM. 2006. Relationships between IQ and regional cortical gray matter thickness in healthy adults. Cereb Cortex. [Epub ahead of print].
59. Nichols TE, Holmes AP. 2001. Nonparametric permutation tests for functional neuroimaging: a primer with examples. Hum Brain Mapp. 15:1-25.
60. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, et al. 2003. Neuroanatomical abnormalities before and after onset of psychosis: a crosssectional and longitudinal MRI comparison. Lancet. 361:281-288.
61. Parikh V, Khan MM, Mahadik SP. 2004. Olanzapine counteracts reduction of brain-derived neurotrophic factor and TrkB receptors in rat hippocampus produced by haloperidol. Neurosci Lett. 356:135-139.
62. Peters A, Sethares C. 2004. Oligodendrocytes, their progenitors and other neuroglial cells in the aging primate cerebral cortex. Cereb Cortex. 14:995-1007.
63. Reinke A, Martins MR, Lima MS, Moreira JC, Dal-Pizzol F, Quevedo J. 2004. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci Lett. 372:157-160.
64. Selemon LD, Lidow MS, Goldman-Rakic PS. 1999. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry. 46:161-172.
65. Shattuck DW, Sandor-Leahy SR, Schaper KA, Rottenberg DA, Leahy RM. 2001. Magnetic resonance image tissue classification using a partial volume model. Neuroimage. 13:856-876.
66. Sowell ER, Peterson BS, Thompson PM, Welcome SE, Henkenius AL, Toga AW. 2003. Mapping Cortical Change Across the Human Lifespan. Nature Neuroscience. 6(3):309-315.
67. Szeszko PR, Ardekani BA, Ashtari M, Kumra S, Robinson DG, Sevy S, Gunduz-Bruce H, Malhotra AK, Kane JM, Bilder RM, et al. 2005. White matter abnormalities in first-episode schizophrenia or schizoaffective disorder: a diffusion tensor imaging study. Am J Psychiatry. 162:602-605.
68. Thompson PM, Dutton RA, Hayashi KM, Toga AW, Lopez OL, Aizenstein HJ, Becker JT. 2005. Thinning of the Cerebral Cortex in HIV/AIDS Reflects CD4+ T-Lymphocyte Decline. Proc Ntl Acad Sci. 102(43):15647-15652.
69. Thompson PM, Hayashi KM, de Zubicaray G, Janke AL, Rose SE, Semple J, Herman D, Hong MS, Dittmer S, Doddrell DM, Toga AW. 2003. Dynamics of Gray Matter Loss in Alzheimer's Disease. Journal of Neuroscience. 23(3):994-1005.
70. Thompson PM, Hayashi KM, Sowell ER, Gogtay N, Giedd JN, Rapoport JL, de Zubicaray GI, Janke AL, Rose SE, Semple J, et al. 2004. Mapping cortical change in Alzheimer's disease, brain development, and schizophrenia. Neuroimage. 23(Suppl. 1): S2-S18.
71. Thompson PM, Lee AD, Dutton RA, Geaga JA, Hayashi KM, Eckert MA, Bellugi U, Galaburda AM, Korenberg JR, Mills DL, et al. 2005.
72. Abnormal cortical complexity and thickness profiles mapped in Williams syndrome. J Neurosci. 25:4146-4158.
73. Thompson PM, Vidal CN, Giedd JN, Gochman P, Blumenthal J, Nicolson R, Toga AW, Rapoport JL. 2001. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA. 98:11650-11655.
74. Vidal CN, Hayashi KM, Geaga JA, Sui Y, McLemore LE, Alaghband Y, Giedd JN, Gochman P, Blumenthal J, Gogtay N, et al. 2006. Dynamically spreading frontal and cingulate deficits mapped in adolescents with schizophrenia. Arch Gen Psychiatry. 63:25-34.
75. Wang HD, Deutch AY. 2008. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Proc Natl Acad Sci USA. 33(6):1276-1286.
76. Wang HD, Dunnavant FD, Jarman T, Deutch AY. 2004. Effect of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology. 29:1230-1238.
77. Weinberger DR, McClure RK. 2002. Neurotoxicity, neuroplasticity, and magnetic resonance imaging morphometry: what is happening in the schizophrenic brain? Arch Gen Psychiatry. 59(6):553-558.
78. Woods BT. 1998. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry. 155:1661-1670.
79. Wright AM, Bempong J, Kirby ML, Barlow RL, Bloomquist JR. 1998. Effects of haloperidol metabolites on neurotransmitter uptake and release: possible role in neurotoxicity and tardive dyskinesia. Brain Res. 788:215-222.